[{"id":"55b1a0de-6575-4213-92f4-3ad23c6cc089","acronym":"","url":"https://clinicaltrials.gov/study/NCT07150403","created_at":"2025-09-06T13:44:19.461Z","updated_at":"2025-09-06T13:44:19.461Z","phase":"Phase 2","brief_title":"A Phase II, Open-label, Non-comparative, Randomized Study of Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT07150403","lead_sponsor":"Federation Francophone de Cancerologie Digestive","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-09-02"},{"id":"dacc9da3-7f50-4fcd-b6ab-f82afa578e33","acronym":"","url":"https://clinicaltrials.gov/study/NCT07025850","created_at":"2025-06-21T13:17:03.504Z","updated_at":"2025-06-21T13:17:03.504Z","phase":"Phase 1/2","brief_title":"Digoxin Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT07025850","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-06-18"},{"id":"ddb28914-edb2-4733-8bbd-06431d3d7e9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856837","created_at":"2025-09-07T01:48:45.276Z","updated_at":"2025-09-07T01:48:45.276Z","phase":"Phase 2","brief_title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","source_id_and_acronym":"NCT06856837","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-03-04"},{"id":"2c844ff3-38e3-4e1a-ab45-51650b975490","acronym":"ST316-101","url":"https://clinicaltrials.gov/study/NCT05848739","created_at":"2023-05-08T15:04:02.971Z","updated_at":"2025-02-25T14:17:54.068Z","phase":"Phase 1","brief_title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT05848739 - ST316-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" PD-L1 • MSI • BRCA","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • BRCA mutation","tags":["PD-L1 • MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-17"},{"id":"676a91c9-2aba-4008-872e-5a9b996188c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06791083","created_at":"2025-02-25T18:40:00.939Z","updated_at":"2025-02-25T18:40:00.939Z","phase":"Phase 2","brief_title":"Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer","source_id_and_acronym":"NCT06791083","lead_sponsor":"First Affiliated Hospital of Fujian Medical University","biomarkers":" CD8 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-01-24"},{"id":"358678b3-c9a6-4c23-828d-5c45b7da8cf5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06553781","created_at":"2025-02-27T08:07:07.607Z","updated_at":"2025-02-27T08:07:07.607Z","phase":"","brief_title":"A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide in Second-line and Subsequent Treatment of Advanced Melanoma","source_id_and_acronym":"NCT06553781","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-08-14"},{"id":"75a2f882-37f5-404f-a62e-867c007e7b0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06543836","created_at":"2025-02-27T08:03:16.048Z","updated_at":"2025-02-27T08:03:16.048Z","phase":"Phase 2","brief_title":"ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer","source_id_and_acronym":"NCT06543836","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Stivarga (regorafenib) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-08-08"},{"id":"f1ad940d-0158-42e2-8647-51b32c5f7ee6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565417","created_at":"2022-10-04T15:57:50.214Z","updated_at":"2024-07-02T16:35:06.273Z","phase":"Phase 1/2","brief_title":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05565417","lead_sponsor":"Immunitas Therapeutics","biomarkers":" KRAS • BRAF • ALK • PIK3CA • MET • MSI","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation","tags":["KRAS • BRAF • ALK • PIK3CA • MET • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • IMT-009"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-03"},{"id":"4778a574-5f01-405a-9873-c9cc5d26ae19","acronym":"","url":"https://clinicaltrials.gov/study/NCT03903705","created_at":"2021-01-18T19:12:53.641Z","updated_at":"2024-07-02T16:35:07.454Z","phase":"Phase 1/2","brief_title":": A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors","source_id_and_acronym":"NCT03903705","lead_sponsor":"Hutchmed","biomarkers":" PD-L1 • ALK • ROS1 • IFNA1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion","tags":["PD-L1 • ALK • ROS1 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 381","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-25"},{"id":"a52c3104-0f9a-4050-865e-f342d9805c67","acronym":"HCCSC-C03","url":"https://clinicaltrials.gov/study/NCT05661357","created_at":"2022-12-22T15:59:20.868Z","updated_at":"2024-07-02T16:35:09.314Z","phase":"Phase 4","brief_title":"Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression","source_id_and_acronym":"NCT05661357 - HCCSC-C03","lead_sponsor":"Zhongnan Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 mutation • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 mutation • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Fruzaqla (fruquintinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-17"},{"id":"26e9db97-f370-4e99-8363-6b01cab5688a","acronym":"SALVLIV","url":"https://clinicaltrials.gov/study/NCT06199232","created_at":"2024-01-12T00:20:10.946Z","updated_at":"2024-07-02T16:35:22.196Z","phase":"","brief_title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","source_id_and_acronym":"NCT06199232 - SALVLIV","lead_sponsor":"Peking University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • irinotecan • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 01/23/2026","primary_completion_date":" 01/23/2026","study_txt":" Completion: 01/23/2027","study_completion_date":" 01/23/2027","last_update_posted":"2024-01-25"},{"id":"2652e287-e262-4cad-a91d-ca616f9a9ce6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05522738","created_at":"2022-08-31T15:56:48.611Z","updated_at":"2024-07-02T16:35:24.270Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05522738","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 08/10/2022","start_date":" 08/10/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-08"},{"id":"102b4a61-44f1-4cba-b968-85bc74835371","acronym":"FISSION","url":"https://clinicaltrials.gov/study/NCT06091423","created_at":"2023-10-19T17:13:11.911Z","updated_at":"2024-07-02T16:35:27.512Z","phase":"Phase 2","brief_title":"XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study","source_id_and_acronym":"NCT06091423 - FISSION","lead_sponsor":"Xiaofeng Chen","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • capecitabine • oxaliplatin • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 10/25/2023","start_date":" 10/25/2023","primary_txt":" Primary completion: 11/25/2025","primary_completion_date":" 11/25/2025","study_txt":" Completion: 11/25/2026","study_completion_date":" 11/25/2026","last_update_posted":"2023-11-30"},{"id":"30dfe7a5-cae5-4e9c-af91-e3ed9913d81a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06099314","created_at":"2023-10-25T19:13:58.396Z","updated_at":"2024-07-02T16:35:31.706Z","phase":"","brief_title":"Fruquintinib in the Cross-line Treatment of Refractory mCRC","source_id_and_acronym":"NCT06099314","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-10-25"},{"id":"0655dcd3-2ff9-4898-8465-39349aee524a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06094868","created_at":"2023-10-23T19:13:43.055Z","updated_at":"2024-07-02T16:35:32.146Z","phase":"Phase 2","brief_title":"Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer","source_id_and_acronym":"NCT06094868","lead_sponsor":"Second Affiliated Hospital of Nanchang University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • capecitabine • oxaliplatin • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-23"},{"id":"f6337414-9975-408c-9a77-c574d3607574","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078670","created_at":"2023-10-12T22:13:53.034Z","updated_at":"2024-07-02T16:35:33.749Z","phase":"Phase 1/2","brief_title":"PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06078670","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" PD-L1 • BRCA1 • BRCA2 • CHEK2","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRCA1 • BRCA2 • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-10-12"},{"id":"af6835fd-61cf-41f6-b279-c0c972579d16","acronym":"FRESCO-2","url":"https://clinicaltrials.gov/study/NCT04322539","created_at":"2021-01-18T20:56:36.196Z","updated_at":"2024-07-02T16:35:36.991Z","phase":"Phase 3","brief_title":"A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04322539 - FRESCO-2","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" MSI","pipe":" | ","alterations":" RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 691","initiation":"Initiation: 08/12/2020","start_date":" 08/12/2020","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-09-14"},{"id":"05075952-55a7-42e5-98df-eb7f2ac450fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06031376","created_at":"2023-09-11T16:10:31.705Z","updated_at":"2024-07-02T16:35:37.518Z","phase":"","brief_title":"Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC","source_id_and_acronym":"NCT06031376","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" RAS","pipe":" | ","alterations":" RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-09-11"},{"id":"ec44533f-4eb5-491d-92bc-8c763456a04b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010888","created_at":"2023-08-25T15:08:21.578Z","updated_at":"2024-07-02T16:35:39.030Z","phase":"Phase 2","brief_title":"Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC","source_id_and_acronym":"NCT06010888","lead_sponsor":"Fudan University","biomarkers":" BRAF • UGT1A1","pipe":" | ","alterations":" BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation","tags":["BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-08-25"},{"id":"208c1d8e-ad83-4803-8b5c-193b9a7eb2cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993702","created_at":"2023-08-15T19:10:28.743Z","updated_at":"2024-07-02T16:35:39.976Z","phase":"","brief_title":"TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer","source_id_and_acronym":"NCT05993702","lead_sponsor":"China Medical University, China","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-08-15"},{"id":"e305e992-0313-4c67-bcd7-6800ec7e6eeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05982834","created_at":"2023-08-09T14:09:20.470Z","updated_at":"2024-07-02T16:35:40.485Z","phase":"Phase 1/2","brief_title":"Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC","source_id_and_acronym":"NCT05982834","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-09"},{"id":"6e4b55ea-6316-4cd0-bc08-8e0da9b09848","acronym":"","url":"https://clinicaltrials.gov/study/NCT05954429","created_at":"2023-07-20T23:10:54.535Z","updated_at":"2024-07-02T16:35:42.486Z","phase":"Phase 2","brief_title":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study","source_id_and_acronym":"NCT05954429","lead_sponsor":"Junjie Peng","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" BRAF mutation • RAS wild-type","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-07-20"},{"id":"b1c11e07-011b-4385-bd78-66d081acc284","acronym":"","url":"https://clinicaltrials.gov/study/NCT05928312","created_at":"2023-07-03T16:10:30.818Z","updated_at":"2024-07-02T16:35:42.459Z","phase":"","brief_title":"Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer","source_id_and_acronym":"NCT05928312","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • irinotecan • Fruzaqla (fruquintinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 08/28/2023","start_date":" 08/28/2023","primary_txt":" Primary completion: 06/28/2025","primary_completion_date":" 06/28/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-07-20"},{"id":"5e188b36-d651-47aa-9f49-29063622e84f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05721651","created_at":"2023-02-10T16:00:34.692Z","updated_at":"2024-07-02T16:35:50.797Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study","source_id_and_acronym":"NCT05721651","lead_sponsor":"Wu Jun","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-04-12"}]